The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 09, 2017

Filed:

Apr. 22, 2013
Applicants:

Stc.unm, Albuquerque, NM (US);

University of Kansas, Lawrence, KS (US);

Inventors:

Angela Wandinger-Ness, Albuquerque, NM (US);

Larry Sklar, Albuquerque, NM (US);

Zurab Surviladze, Albuquerque, NM (US);

Tudor Oprea, Albuquerque, NM (US);

Laurie Hudson, Albuquerque, NM (US);

Jeffrey Aube, Lawrence, KS (US);

Jennifer E. Golden, Olathe, KS (US);

Chad E. Schroeder, Lawrence, KS (US);

Denise S. Simpson, Fairborn, KS (US);

Julica J. Noth, Munich, DE;

Assignees:

STC.UNM, Albuquerque, NM (US);

UNIVERSITY OF KANSAS, Lawrence, KS (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); A61K 45/06 (2006.01); C07D 231/06 (2006.01); A61K 31/403 (2006.01); A61K 31/407 (2006.01);
U.S. Cl.
CPC ...
A61K 31/403 (2013.01); A61K 31/407 (2013.01); A61K 31/415 (2013.01); A61K 45/06 (2013.01); C07D 231/06 (2013.01);
Abstract

The present invention relates to molecules which function as selective modulators (i.e., inhibitors and agonists, preferably inhibitors) of the Ras-homologous (Rho) family of small GTPases, in particular, Cdc42 GTPase and their use to treat diseases, for example cancers, including metastatic cancer, where Cdc42 GTPase is overexpressed or hyperactivated, genetic and acquired diseases where activation of Cdc42 GTPase plays a pivotal role (e.g., neurodegenerative diseases), rheumatoid arthritis, atherosclerosis, diabetes type I, autosomal polycystic kidney diease, cystic kidney disease, precystic kidney disease and microbial infections. Additionally, compounds according to the present invention may be used to inhibit rejection (graft host response) in transplant patients (pursuant to transplantation), to promote immunosuppression, anti-inflammatory response and to mobilize stem cell (migration) in patients in need, among others.


Find Patent Forward Citations

Loading…